Use of Gocovri to Improve Disability Due to Radiation Encephalopathy
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorWeill Medical College of Cornell University
About this trial
A study to assess the effect of Gocovri (extended-release amantidine) to improve disability as assessed by the disability rating scale (DRS) and cognition as assessed by the Montreal Cognitive Assessment (MoCA) test in patients with radiation encephalopathy.
Eligibility criteria
Qualifiers
Individuals ≥ 18 years of age.
Individuals with caregivers who are able to complete survey assessments for this study.
Prior brain radiation treatment.
Evidence of moderate-severe confluent white matter hyperintensity on MRI brain scan as judged by neuroradiology impression 0-5 years prior to enrollment.
Disqualifiers
Pregnant or breastfeeding.
Patients with growing brain lesions or those requiring escalating doses of tumor-directed treatment..
Patients requiring doses of Dexamethasone higher than 4 mg or escalating doses of Dexamethasone
Patients taking Amantadine or with prior usage of Amantadine.
Trial design
Treatments tested in this trial
- Gocovri (extended-release amantidine)
Treatment groups
24 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov